

## Drug Utilization Review Board Meeting

**February 6, 2018**

Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
<b>Drug Reviews</b>			
<b>Cytokine Modulators, Rheumatoid Arthritis</b>			
	Kevzara (Subcutaneous) Injection	Non-PDL	NP/PA
<b>Cytokine Modulators, Psoriasis</b>			
	Siliq (Subcutaneous) Injection	Non-PDL	NP/PA
	Tremfya (Subcutaneous) Injection	Non-PDL	NP/PA
<b>Antivirals, Hepatitis C Direct-Acting Agents</b>			
	Vosevi (Oral) Tablet	Non-PDL	NP/PA
<b>Antiparkinson Agents</b>			
	Xadago (Oral) Tablet	Non-PDL	NP/PA

PDL=Preferred Drug List; P=preferred; NP=non-preferred; PA=prior authorization